Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
ENLV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $4.59
Previous CloseN/A
Volume59.48K
Average Volume (3M)195.40K
Market Cap
$22.98M
Enterprise Value$48.35M
Total Cash (Recent Filing)$9.74M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 23, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding21,989,536
10 Day Avg. Volume164,657
30 Day Avg. Volume195,395
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap2.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-57.91
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$7.00Price Target Upside586.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Enlivex News
PremiumCompany Announcements
Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment
PremiumCompany Announcements
Enlivex Reports Promising Interim Results in Osteoarthritis Trial
PremiumCompany Announcements
Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEnlivex reported its 2Q24 financial results, closing the period with $25.9M in cash and short-term deposits.
Regulatory ApprovalsThe Danish Medicines Agency has authorized the initiation of the Phase 2 stage of the company’s multi-country Phase 1/2 trial in moderate and severe knee osteoarthritis (OA) patients.
Bears Say
Financial LossThe company recorded a 2Q24 net loss of $0.16 per share, moderately narrower than the forecast for a net loss of $0.22 per share.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
10.22% Other Institutional Investors
88.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $0.81 and its highest was $4.59 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $22.98M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is May 23, 2025 which is in 59 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate is -0.16.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 21,989,536 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went up 2.19%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
---
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
---
ENLV Stock 12 Month Forecast
Average Price Target
$7.00
▲(586.27% Upside)
Technical Analysis
Bluebird Bio
―
Karyopharm Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Cyclerion Therapeutics
―
Best Analysts Covering ENLV
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-34.27%
reiterated a buy rating 5 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.27% per trade.
---